Short answer
Sometimes — and sometimes not. Meta scrutinizes health and wellness advertising. Whether a peptide or research-compound offer can run depends on the actual product, how it is positioned, where it is sold, how claims are made in ads and on-site, and how those elements interact with current Meta Advertising Policies and review systems.
There is no universal yes. Two brands both selling “peptides” can face different outcomes if one markets a permitted wellness framing with careful claims and another implies medical outcomes, ships into restricted contexts, or uses a landing page that contradicts the ad. Eligibility is case-dependent. Anyone selling a blanket guarantee is ignoring how review typically works.
What “eligibility” actually means
Eligibility is not only “did this ad get approved once.” It includes whether the product category is allowed to advertise on Meta for your markets, whether the claims you need to convert customers are permitted and truthful, whether the landing page stays consistent with the ad, and whether your business presence (Page, domain, transparency) looks coherent under review.
Jurisdiction matters. Rules and enforcement priorities can differ by destination market and by how a product is classified where you sell it. A positioning that seems acceptable in one context may be non-viable in another. Your legal and regulatory obligations are separate from Meta’s advertising rules — satisfying one does not automatically satisfy the other.
Claims matter as much as the SKU list. Outcome language, disease implications, before/after framing, and personal-attribute targeting or copy can trigger scrutiny even when the product itself is not the only issue. Landing pages that escalate claims beyond the ad commonly create reject or restriction pressure.
Why peptide advertising is scrutinized
Health-adjacent offers often trigger reviews related to misleading claims, personal attributes, restricted goods and services categories, and landing-page consistency — depending on creative and destination. Meta’s systems and human review may evaluate ads, Pages, and websites together. A careful primary text with an aggressive on-page medical claim is still a risk package.
Account and Business Manager quality also matter operationally. Fragile setups — unclear ownership, payment problems, high reject rates, tangled partners — typically fail under load even when a single creative looks restrained. Infrastructure does not create eligibility for a prohibited offer, but weak infrastructure can make an otherwise careful launch unstable.
What reviewers effectively look at
In practice, expect scrutiny across the full path from ad to conversion, not only the headline. Exact enforcement can change with current Meta policies and automated systems, so treat the following as operational focus areas rather than a complete legal checklist.
- Product eligibility and category fit for the markets you target
- Medical, disease, or outcome claims in ads, images, video, and on-page copy
- Landing-page consistency with the ad — including popups, FAQ, and linked pages
- Business / Page transparency and whether the advertiser identity is clear
- Ad account and Business Manager quality signals, payment health, and prior rejects
- Personal-attribute language that implies knowledge of a user’s health condition
When you should NOT advertise
If the product appears prohibited for advertising on Meta under current policies for your use case, do not force it live through agency accounts, new Pages, or creative tricks. Infrastructure does not override category eligibility.
If the claims required to sell the product cannot be made truthfully and within Meta’s advertising standards as they apply to your creative and landing page, pause paid social for that offer until positioning changes — or choose channels where your compliant messaging can work.
If the landing page contradicts the ad, buries material information, or escalates into medical outcome territory the ad avoided, fix the site before spending. If you cannot describe the product honestly without triggering the issues above, eligibility review before spend protects more than a rejected campaign does.
Do not use cloaking, geo-swapped “review” pages, or hidden claim sets as a strategy. Those approaches are policy-evasion patterns and typically increase long-term account risk. The compliant path is to change the offer, claims, or channel — not to disguise them.
A practical decision path
Work in order: product and market eligibility, claim inventory across ads and site, landing-page consistency, business transparency, then account architecture. If step one fails, stop. If claims fail, rewrite or do not advertise. If only architecture is weak, fix permissions, tracking ownership, and account health before scaling tests.
Write the decision down. A one-page internal note that states “eligible / not eligible / needs repositioning,” lists the claims you will allow, and names the destination URL reduces the chance that media buyers invent angles under pressure. When Meta rejects an ad, compare the reject to that note before changing accounts or creatives.
When you need a second opinion, ask for a compliance-aware review that can decline the offer. A useful partner will say “not like this” when needed. They should not invent Meta partnership status, approval rates, or guarantees. Your team remains responsible for product legality, labeling, and the claims you publish.
How this differs from a compliance checklist
This page answers the eligibility question: whether you should advertise a given peptide offer on Facebook and Instagram at all. A compliance checklist assumes you may proceed and then walks through claims, creative, landing pages, transparency, tracking, and account health before launch. Rejection guides explain why campaigns fail after you try. Keep those intents separate so teams do not treat infrastructure as a substitute for eligibility.